BY: Kerri Fitzgerald
Nearly three years after treatment with the chimeric antigen receptor T-cell therapy ciltacabtagene autoleucel (cilta-cel), the risk of death was reduced by 45% compared with standard of care.
María-Victoria Mateos, MD, PhD, of the University of Salamanca in Spain, presented these long-term CARTITUDE-4 study results at the European Society for Blood and Marrow Transplantation (EBMT) 51st Annual Meeting in Florence, Italy.
Patients (n=419) were randomized to receive cilta-cel (n=208) or standard of care, consisting of pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone (n=211).
Median overall survival (OS) was not reached with cilta-cel or standard of care; the 30-month OS rates were 76% and 64%, respectively.
Median progression-free survival (PFS) was also not reached in either arm; 30-month PFS was 59% and 26%, respectively.
The overall response rate was 85% with cilta-cel versus 67% with standard of care, and the overall measurable residual disease-negativity rate was 62% versus 18%, respectively.
Quality of life improved with cilta-cel: The median time to symptom worsening based on the MySIm-Q measurement was not reached with cilta-cel versus 34.33 months with standard of care (P<.0001).
In both groups, 97% of patients experienced grade 3/4 treatment-related adverse events, the most common of which was cytopenia. Treatment-related infections occurred more in the cilta-cel arm: 63% versus 76%. Hematologic second primary malignancies occurred in seven cilta-cel-treated patients and just one standard of care-treated patient.
Fifty people in the cilta-cel cohort died compared with 82 in the standard of care arm; 21 and 51 deaths, respectively, were related to disease progression.
Reference
Mateos MV, et al. Overall survival (OS) with ciltacabtagene autoleucel (cilta-cel) versus standard of care (SOC) in lenalidomide (Len)-refractory multiple myeloma (MM): phase 3 CARTITUDE-4 study update. Abstract OS14-02. Presented at the EBMT 51st Annual Meeting; March 30-April 2; Florence, Italy.
